GH RESEARCH PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.81 USD | +6.84% |
|
+9.67% | +120.86% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 666M |
|---|---|---|---|---|---|
| Net income 2024 * | -43M | Net income 2025 * | -72M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 237M | Net cash position 2025 * | 265M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-16
x | P/E ratio 2025 * |
-10.9
x | Employees | 49 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.61% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +6.84% | ||
| 1 week | +9.67% | ||
| Current month | +16.88% | ||
| 1 month | +15.93% | ||
| 3 months | +59.13% | ||
| 6 months | +56.03% | ||
| Current year | +120.86% |
1 week
11.52
12.82
1 month
10.3012.82
Current year
5.1212.82
1 year
5.0514.64
3 years
5.0530.43
5 years
5.0530.43
10 years
5.0530.43
| Managers | Title | Age | Since |
|---|---|---|---|
Magnus Halle
FOU | Founder | 27 | 17-12-31 |
Theis Terwey
CEO | Chief Executive Officer | 48 | 17-12-31 |
Julie Ryan
DFI | Director of Finance/CFO | 38 | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Duncan Moore
BRD | Director/Board Member | 65 | 21-09-23 |
| Founder | 55 | 17-12-31 | |
Michael Forer
BRD | Director/Board Member | 58 | 20-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 12.81 | +6.84% | 56,443 |
| 24-05-09 | 11.99 | 0.00% | 60,392 |
| 24-05-08 | 11.99 | -0.75% | 36,553 |
| 24-05-07 | 12.08 | +3.34% | 76,680 |
| 24-05-06 | 11.69 | +0.09% | 36,273 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.81
USD
Average target price
32
USD
Spread / Average Target
+149.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +120.86% | 666M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- GHRS Stock
